Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Return on Capital Employed: 2021-2025

Historic Return on Capital Employed for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Sep 2025 value amounting to 0.07%.

  • Kiniksa Pharmaceuticals International's Return on Capital Employed rose 13.00% to 0.07% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.07%, marking a year-over-year increase of 13.00%. This contributed to the annual value of -0.10% for FY2024, which is 4.00% down from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Return on Capital Employed stood at 0.07% for Q3 2025, which was up 675.79% from 0.01% recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Return on Capital Employed ranged from a high of 0.09% in Q2 2023 and a low of -0.79% during Q4 2021.
  • Over the past 3 years, Kiniksa Pharmaceuticals International's median Return on Capital Employed value was -0.04% (recorded in 2023), while the average stood at -0.02%.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Return on Capital Employed soared by 81bps in 2022, and later fell by 15bps in 2024.
  • Quarterly analysis of 5 years shows Kiniksa Pharmaceuticals International's Return on Capital Employed stood at -0.79% in 2021, then surged by 81bps to 0.02% in 2022, then declined by 8bps to -0.06% in 2023, then dropped by 4bps to -0.10% in 2024, then climbed by 13bps to 0.07% in 2025.
  • Its Return on Capital Employed was 0.07% in Q3 2025, compared to 0.01% in Q2 2025 and -0.03% in Q1 2025.